Skip to content

to find the utility of parasikayavanyadi capsule in sleeplesness

EVALUATION OF PARASIKAYAVANYADI CAPSULE IN THE MANAGEMENT OF ANIDRA w s r TO INSOMNIA

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2012/12/003174
Enrollment
50
Registered
2012-12-04
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- INSOMNIA

Interventions

Intervention1: PARASIKAYAVANYADI CAPSULE for ANIDRA W R S INSOMNIA: 500 MG EACH CAPSULE WITH MILK TOTALY 5 CAPSULE ONLY ONE DOSE BED TIME FOR ONE MONTH ONLY Control Intervention1: RUNNING ALLOPATHIC

Sponsors

AYUSH
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: patients suffering from following type of disturbed sleep pattern Sleep onset insomnia Difficulty taking sleep at the beginning of the night Sleep maintenance insomnia Difficulty maintain the sleep Nocturnal awakenings Difficulty to retuning to sleep after awakening in the middle of the night or wakening early in the morning Rebound insomnia Patients who has developed dependence to sedatives Circadian rhythm disorders Sleeping pattern changes Patients having insomnia more than 2 weeks less than 6 months Patients of insomnia with mild hypertension mild depression and anxiety disorders without any complaints of any other major diseases

Exclusion criteria

Exclusion criteria: patients less than 16 years and more than 75 years Patients suffering from fatal familial insomnia Insomnia with major psychiatric illness like Schizophrenia depressive psychosis Epilepsy Patients having advanced chronic illness like Bronchial asthma Diabetes mellitus malignancy Liver cirrhosis chronic renal failure Patients with alcohol or drug dependency will be excluded Patients having acute illness like cardiovascular accidents myocardial infarction chronic obstructive pulmonary disease Pregnant woman and planning to be pregnant within six months

Design outcomes

Primary

MeasureTime frame
PITTSBURGH INSOMNIA RATING SCALE HAMILTONS ANXIETY RATING SCALE HAMILTON DEPRESSION RATING SCALE HOLEMS AND RAHES STRESS RATING SCALE S CORTISOL LEVEL ANALYSIS FOR DRUG EFFECT AS AN OBJECTIVE CRITIRIEATimepoint: EFFECT OF DRUG IS ASSED AFTER ONE MONTH

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDR HM CHANDOLA

IPGT RA

kaurmandip22@yahoo.com09427572306

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026